Navigation Links
Orexigen Therapeutics to Present at Upcoming Conferences
Date:2/9/2012

SAN DIEGO, Feb. 9, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will be presenting at two upcoming investor conferences.  The details are as follows:

The 14th Annual BIO CEO & Investor Conference
Date:
February 13, 2012
Time:  1:30pm Eastern Time
Location:  Waldorf Astoria, New York
Speaker:  Michael Narachi, President and Chief Executive Officer

Leerink Swann Global Healthcare Conference
Date:
February 15, 2012
Time:  8:00am Eastern Time
Location:  Waldorf Astoria, New York
Speaker:  Michael Narachi, President and Chief Executive Officer

To listen to the live webcast or a replay of the presentations, please visit the Investor Relations section of the company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.

About Orexigen TherapeuticsOrexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Contrave® has completed Phase 3 clinical trials for which a New Drug Application has been submitted and reviewed by the FDA, and the FDA has agreed to a SPA for the Contrave outcomes trial.  The Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.Corporate Contacts: OrexigenOrexigen

MediaJay Hagan

Denise PowellChief Business Officer

WCG(858) 875-8673

(510)
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
2. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
3. Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting
4. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
5. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
6. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
7. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
8. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
9. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
10. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
11. Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014 The global consumption of squalene / squalane ... a natural skin-identical chemical that finds applications in various end ... pharmaceuticals, and in other applications like high grade lubrication, and ... few major players and is regionally segregated. Sophim ( ... Co. Ltd. ( Japan ), SeaDragon Marine Oils ...
(Date:9/17/2014)... , Sept. 17, 2014  MiMedx Group, Inc. ... processor and marketer of patent protected regenerative biomaterials ... today the publication of another peer-reviewed clinical study.    ... A Multi-center Randomized Controlled Clinical Trial Evaluating the ... Membrane Allografts and Multi-layer Compression Therapy vs. Multi-layer ...
(Date:9/17/2014)... Franklin, MA (PRWEB) September 17, 2014 ... pre-engineered version of its TerraPure tank . This ... tanks is molded from FDA-compliant linear polyethylene and available ... seven pre-installed fittings and ships in two weeks or ... same features and benefits found in Terracon’s existing TerraPure ...
(Date:9/17/2014)... SAN FRANCISCO, Calif. , Sept. 17, 2014 /PRNewswire/ ... ), a molecular diagnostics company pioneering the field of ... Hall to chief operating officer. Mr. Hall ... spearhead the company,s commercial entry into endocrinology. Since 2012, ... operations, as well as managed care and billing functions. ...
Breaking Biology Technology:Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 2Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 4Terracon Introduces Pre-Engineered TerraPure® Tank for Ultrapure Water Applications 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 4
... Collaboration will leverage HUYA,s growing Chinese bioscience network , ... 15 HUYA Bioscience International, a leader in US/China ... subsidiary, N.V. Organon. Schering-Plough has selected HUYA to identify ... lead, preclinical and clinical drug candidates in specific therapeutic ...
... VIENNA, Austria, December 15 bwin, the world,s,leading online ... Health Alliance, a Harvard Medical School Teaching Affiliate, have,just ... The,research objective is to use scientific evidence to create ... of the,world,s largest longitudinal study. , ...
... (Nasdaq: PRXL ), a leading global ... been named the "Best Contract,Research Organization (CRO)" by ... PAREXEL at the fourth annual Scrip Awards ceremony ... Scrip Awards are designed to,celebrate innovation and a ...
Cached Biology Technology:HUYA Bioscience Announces Agreement to Provide Schering-Plough With Drug Development Candidates From China 2HUYA Bioscience Announces Agreement to Provide Schering-Plough With Drug Development Candidates From China 3bwin and Harvard Medical School Faculty Sign 5-Year Research Cooperation Agreement 2PAREXEL Receives Best CRO Award from Scrip 2PAREXEL Receives Best CRO Award from Scrip 3PAREXEL Receives Best CRO Award from Scrip 4
(Date:9/17/2014)... as an EC-FP5 four-year project, delivering its first release ... successful participations in several EC projects, as a part ... project (EU BON), to increase the general awareness of ... the general dissemination of the Fauna Europaea results, the ... its novel e-Publishing tools to prepare data papers for ...
(Date:9/17/2014)... Copenhagen Centre for Social Evolution and Yale University offers ... weight and -length can partially predict the likelihood of ... and schizophrenia later in life. The study analyzed medical ... diagnoses for up to 30 years, and adjusted for ... published today in the Proceedings of the Royal ...
(Date:9/17/2014)... the human retinoblastoma protein gene are a leading cause ... turned to fruit fly eyes to unlock the secrets ... paper featured on the cover of the current issue ... State University researchers provide the first detailed examination of ... the human cancer gene, said Irina Pushel, MSU undergraduate ...
Breaking Biology News(10 mins):Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Abnormal properties of cancer protein revealed in fly eyes 2
... flamingos are a curiosity of nature. Now a new discovery ... oddity that helps flamingos eat: erectile tissue. , Flamingos are ... water, they bend their necks, tilt their bills upside down ... large tongue acts like a piston, sucking water into the ...
... have interfered with the brain's ability to control an animal's ... published in the latest issue of the Proceedings of the ... is based on the identification of a gene - CPT1c ... According to the researchers, the CPT1c gene protects against weight ...
... neighborhood to a friend's house or deciding on a ... can make decisions based on incomplete information and update ... of such sophisticated decision making in the cerebral cortex, ... studied and little understood," according to Wako Yoshida and ...
Cached Biology News:Ohio University researchers discover evolutionary oddity in flamingos 2Eat less, weigh more? Enzyme makes lean mice 'susceptible' to dietary fat 2Eat less, weigh more? Enzyme makes lean mice 'susceptible' to dietary fat 3Where we change our mind 2
... and M.W. Turner (1997). ... step-by-step methods for the ... molecules, the use of ... analytical probes and as ...
Request Info...
LabFax: Immunochemistry...
Edited by P.J. Delves (1997) An up-to-date review of antibody-raising technologies, this volume provides researchers with immediate access to the protocols they require every day....
Biology Products: